Top

Cancer Chemotherapy and Pharmacology

Published in:

01-10-2012 | Original Article

The relationship between Helicobacter pylori infection and the effects of chemotherapy in patients with advanced or metastatic gastric cancer

Authors: In Keun Choi, Hwa Jung Sung, Ju-Han Lee, Jun Suk Kim, Jae Hong Seo

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2012

Abstract

Purpose

Several reports have shown a better prognosis in gastric cancer patients who are positive for Helicobacter pylori (HP) infection compared with negative cases. However, there are currently no studies that investigate the relationship between HP infection and the effects of chemotherapy in gastric cancer patients. In this study, we report the relationship between HP infection and chemotherapy effects in patients with advanced or metastatic gastric cancer.

Methods

Sixty-one patients with advanced or metastatic gastric cancer were enrolled in this study. Biopsies were conducted around the tumor site to determine HP status. Patients were then treated with combination 5-FU and cisplatin-based chemotherapy. And we compared chemotherapy response rate and overall survival rate between HP infection group and without HP infection group.

Results

Twelve of 18 patients with HP infection (66.7 %) and 9 of 42 patients without HP infection (21.4 %) showed a partial response to chemotherapy (Chi square P = 0.001). Patients with HP infection had a median survival time of 13 months (95 % CI, 6.9–19.1 months), which was significantly longer than that of patients without HP infection (9 months; P = 0.027, log-rank test).

Conclusions

Patients with advanced or metastatic gastric cancer with concomitant HP infection had a better response to chemotherapy and had an improved overall prognosis compared with patients without HP infection. Further studies are warranted to confirm these findings.

Nomura AM, Kolonel LN, Miki K et al (2005) Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. J Infect Dis 191:2075–2081PubMedCrossRef

Meimarakis G, Winter H, Assmann I et al (2006) Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol 7:211–222PubMedCrossRef

Marrelli D, Pedrazzani C, Berardi A et al (2009) Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer 115:2071–2080PubMedCrossRef

Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181

Stadtlander CT, Waterbor JW (1999) Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis 20:2195–2208PubMedCrossRef

Hansson LE, Engstrand L, Nyren O et al (1993) Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology 105:1098–1103PubMed

Chow WH, Blaser MJ, Blot WJ et al (1998) An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 58:588–590PubMed

Ohno S, Tomisaki S, Oiwa H et al (1995) Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg 180:577–582PubMed

Helicobacter and Cancer Collaboration Group (2001) Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49:347–353

10.

Malaty HM, Kim JG, Kim SD, Graham DY (1996) Prevalence of Helicobacter pylori infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 143:257–262PubMedCrossRef

11.

Lee HJ, Yang HK, Ahn YO (2002) Gastric cancer in Korea. Gastric Cancer 5:177–182PubMedCrossRef

12.

Kohli Y, Tanaka Y, Kato T, Ito S (1993) Endoscopic diagnosis of Helicobacter pylori distribution in human gastric mucosa by phenol red dye spraying method. Nihon Rinsho 51:3182–3186PubMed

13.

Iseki K, Tatsuta M, Iishi H, Baba M, Ishiguro S (1998) Helicobacter pylori infection in patients with early gastric cancer by the endoscopic phenol red test. Gut 42:20–23PubMedCrossRef

14.

Araujo-Filho I, Brandao-Neto J, Pinheiro LA, Azevedo IM, Freire FH, Medeiros AC (2006) Prevalence of Helicobacter pylori infection in advanced gastric carcinoma. Arq Gastroenterol 43:288–292PubMedCrossRef

15.

Caruso ML, Fucci L (1990) Histological identification of Helicobacter pylori in early and advanced gastric cancer. J Clin Gastroenterol 12:601–602PubMed

16.

Tang YL, Gan RL, Dong BH, Jiang RC, Tang RJ (2005) Detection and location of Helicobacter pylori in human gastric carcinomas. World J Gastroenterol 11:1387–1391PubMed

17.

Hobsley M, Tovey FI, Holton J (2007) Helicobacter pylori and gastric cancer: neither friend nor foe. Gastroenterology 132:2076PubMedCrossRef

18.

Qiu HB, Zhang LY, Keshari RP et al (2010) Relationship between H. pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer 10:374PubMedCrossRef

19.

Kang SY, Han JH, Ahn MS et al. (2012) Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer 130:948–958

20.

Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269PubMedCrossRef

21.

Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM (2001) Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 125:1–9PubMedCrossRef

Title: The relationship between Helicobacter pylori infection and the effects of chemotherapy in patients with advanced or metastatic gastric cancer
Authors: In Keun Choi
Hwa Jung Sung
Ju-Han Lee
Jun Suk Kim
Jae Hong Seo
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1944-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases

A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer

A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer

The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer